Veradermics (MANE) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- -$0.64
- Surprise
- —
- Score today
- 5.8/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Veradermics Q2 EPS $(0.58) Beats $(0.65) Estimate — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates MANE Sell at 5.8/10; no pre/post engine snapshot brackets this report.
1 of the last 2 quarters beat the estimate. Next scheduled report: 2026-11-12.
What argues against it
- Concentration risk — Pipeline: VDPHL01
- Quality below floor (2.5 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $98.97
- Price target
- $142.25
- Stop
- $92.04
- Upside to target
- +43.7%
- Reward-to-risk
- 4.4:1
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
MANE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $4.13B
- P/E (fwd)
- -36.8
- 52-week range
- $32.00–$131.24
- Off 52-week high
- 24.6%
- RSI (14)
- 43
- Volume vs avg
- 1.03×
- Score today
- 5.8/10